"The voice for cancer physicians and their patients in Massachusetts."
The Food and Drug Administration approved pemigatinib (Pemazyre, Incyte Corporation) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement. More information.
Massachusetts Society of Clinical Oncologists ©2022
860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | Fax: 781.464.4896 | email: email@example.com